Prednisone
B-Cell Non-Hodgkin Lymphoma
University of WashingtonSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 73/ 100
Competitive context
305 Active assets in the B-Cell Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vindesine Children's Cancer Group, China | Phase 4 | BBB |
Anti-Cd20/Cd3 Monoclonal Antibody Regn1979 University of Birmingham | Phase 3 | BBB |
Cytarabine Children's Cancer Group, China | Phase 4 | BBB |
Methotrexate Children's Cancer Group, China | Phase 4 | BBB |
Zanubrutinib The First Affiliated Hospital of Soochow University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Prednisone is also rated in:
peripheral T-cell lymphoma, not otherwise specifiedActive
BBB
Indicative · Phase 4
74 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →